Next-generation drug reduces endometrial cancer progression and death in trial

A new drug is effective at decreasing the recurrence of, and death from, endometrial cancer, an international study shows. The drug, called sacituzumab tirumotecan (sac-TMT), attaches to a protein on the surface of tumor cells and then delivers a targeted dose of a chemical that leads to cancer cell death.

≈